Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients.
Pierre PeterlinCamille DebordMarion EveillardAlice GarnierAmandine Le BourgeoisThierry GuillaumeMaxime JullienMarie C BénéPatrice ChevallierPublished in: Journal of cellular and molecular medicine (2022)
Myeloid Derived Suppressive Cells (MDSC) are capable to suppress innate and adaptive immune responses, thus favouring solid cancer progression. However, little is known about the role of MDSC in acute myeloid leukaemia (AML). In this monocentric prospective study, 73 adult AML patients, eligible for first-line intensive chemotherapy, were included with the aim to study the influence on long-term outcomes of peripheral blood (PB) levels of monocytic (M) MDSC (M-MDSC) assessed by flow cytometry. A percentage of peripheral M-MDSC higher than 0.55% of leukocytes at diagnosis and a decrease of M-MDSC% after induction came out both as independent negative prognostic factors for leukaemia-free and overall survival.
Keyphrases
- prognostic factors
- acute myeloid leukemia
- immune response
- end stage renal disease
- peripheral blood
- ejection fraction
- induced apoptosis
- flow cytometry
- newly diagnosed
- dendritic cells
- chronic kidney disease
- bone marrow
- squamous cell carcinoma
- oxidative stress
- heavy metals
- patient reported outcomes
- signaling pathway
- free survival
- squamous cell
- extracorporeal membrane oxygenation
- mechanical ventilation
- childhood cancer
- respiratory failure